CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Selected to be Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference

Minneapolis – February 2, 2015 – CVRx, Inc., a private medical device company, announced that the results from the Barostim Therapy for Heart Failure randomized, controlled clinical trial have been accepted by the American College of Cardiology (ACC) for presentation in a Featured Clinical Research Session. Results will be presented by Dr. William Abraham from The Ohio State University on March 16th between 12:30 and 1:45pm (session 414). Additional information on the session can be found at http://accscientificsession.acc.org.

 

About Barostim Therapy™

CVRx completed enrollment of a 146 patient randomized, controlled clinical trial to determine the performance of Barostim Therapy for patients suffering from chronic heart failure with advanced symptoms. Promising results from an earlier study demonstrating clinical improvement and reduced hospitalizations have been presented and published.1 The six month results from the randomized, controlled trial are being prepared for presentation at ACC and manuscript publication.

About Barostim neo

Barostim neois a second generation device that uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat patients suffering from chronic heart failure. The therapy is also a treatment option for patients with resistant hypertension. The system works by electrically activating the baroreceptors, the body’s natural sensors that regulate cardiovascular function. By activating this afferent pathway, Barostim restores sympatho-vagal balance by reducing sympathetic activity and increasing parasympathetic activity.

Key unique benefits:

  • The Barostim neo can be turned on and off to demonstrate acute results;
  • It can be adjusted to meet each patient’s individual therapy needs;
  • It is a reversible treatment;
  • It provides 100 percent compliance to treatment by continuously activating the baroreflex;
  • It is compatible with and complementary to implantable cardio-defibrillators and cardiac resynchronization therapy2 ; and
  • It is now MR Conditional, or safe for use under specified conditions in Europe

 

About Heart Failure

In heart failure, heart function is impaired, resulting in shortness of breath, exercise intolerance and fluid retention. In the United States, heart failure is estimated to affect 5.1 million adults.3 Overall, heart failure is associated with a four-fold increased risk of death and a six to nine times increased risk of sudden cardiac death. The direct and indirect costs of heart failure are estimated to be $32 billion in the United States in 2013.3

 

About CVRx, Inc.

CVRx, Inc. is a privately held company founded in 2001 and headquartered in Minneapolis. The company has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension (high blood pressure). Barostim neohas received CE marking for the treatment of heart failure. Barostim neo has also received CE marking for the treatment of hypertension. It is under clinical evaluation for the treatment of heart failure and hypertension in the United States.

 

 

CVRx Contacts:

John Brintnall

Chief Financial Officer

jbrintnall@cvrx.com

Phone: 763.416.2853

Tom Moore

Vice President of Sales Operations, Marketing

and Field Clinical Support

tmoore@cvrx.com

Phone: 763.258.9039

Footnotes:

  1. Gronda E, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function and cardiac haemodynamics in heart failure: a proof of concept study.   European Journal of Heart Failure 2014; 16(9):977-983
  2. Madershahian N, et al. Baroreflex activation therapy in patients with preexisting implantable cardioverter-defibrilator: Compatible, complementary therapies. Europace Feb, 2014
  3. Go A, Heart Disease and Stroke Statistics. American Heart Association – 2013 Update. Circulation 2013;127:e6-e245

CAUTION: Barostim neo™ is an investigational device and is limited by United States law to investigational use. Exclusively for Clinical Investigations for the treatment of heart failure and resistant hypertension in Canada.

CVRx, HOPE4HF, Barostim neo and Barostim Therapyare trademarks of CVRx, Inc. registered in the United States Trademark Office.

© CVRx, Inc. 2014. All rights reserved.